Durable Response of Low-Dose Afatinib Plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
Wenfeng Fang,Yihua Huang,Jiadi Gan,Yang Shao,Li Zhang
DOI: https://doi.org/10.1016/j.jtho.2019.05.023
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:Most EGFR exon 20 insertion (EGFRex20ins) mutations are refractory to EGFR tyrosine kinase inhibitors.1Yasuda H. Kobayashi S. Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.Lancet Oncol. 2012; 13: E23-E31Abstract Full Text Full Text PDF PubMed Scopus (440) Google Scholar, 2Robichaux J.P. Elamin Y.Y. Tan Z. et al.Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Nat Med. 2018; 24: 638-646Crossref PubMed Scopus (278) Google Scholar Preclinical studies have demonstrated that cetuximab could improve afatinib sensitivity against specific EGFRex20ins-mutant tumors in vitro and in vivo.3Hasegawa H. Yasuda H. Hamamoto J. et al.Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.Lung Cancer. 2019; 127: 146-152Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar Clinical studies have also shown an antitumor effect of combination treatment in some patients with EGFRex20ins mutations.4van Veggel B. de Langen A.J. Hashemi S.M.S. et al.Afatinib and cetuximab in four patients with EGFR exon 20 insertion-positive advanced NSCLC.J Thorac Oncol. 2018; 13: 1222-1226Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar Nevertheless, some patients still required dose reduction because of intolerable adverse events (AEs). Whether other EGFRex20ins-mutated tumors respond to afatinib plus cetuximab combination therapy remains unknown. And a suitable dose of the combination treatment ensuring both clinical effect and better tolerability still entails further exploration. Herein, we are reporting that a patient with NSCLC harboring EGFR M766delinsMATL, a rare EGFRex20ins mutation, achieved long-term disease control with afatinib plus cetuximab, both at a low dose. A 45-year-old Chinese male never-smoker presented with chest pain in May 2017. Computed tomography (CT) revealed a lung mass in the upper right lobe and multiple lesions in the right pleura. Cerebral magnetic resonance imaging and bone scan did not show any lesion. The patient then underwent pulmonary lobectomy and mediastinal lymph node dissection in his local hospital. Postoperative pathology led to the diagnosis of stage IVA lung adenocarcinoma. The patient started receiving pemetrexed/cisplatin chemotherapy on July 18, 2017, and achieved stable disease. The patient complained of worsening chest pain and distress after six cycles of pemetrexed/cisplatin and two cycles of pemetrexed maintenance. A progressive malignant pleural effusion was observed through CT, resulting in disease progression. Thereafter, pleural tissue and blood samples were obtained for targeted next-generation sequencing with use of a customized 422–cancer gene panel (Geneseeq). The patient was confirmed to be positive for EGFR M766delinsMATL, a novel EGFR exon 20 mutation (Fig. 1), accompanied by BRCA1 interacting protein C-terminal helicase 1 gene (BRIP1), notch 1 gene (NOTCH1), retinoblastoma 1 gene (RB1), tumor protein p53 gene (TP53), and thyroid stimulating hormone receptor gene (TSHR) mutations. On the basis of preceding studies, the patient has been treated with afatinib, 40 mg daily, and cetuximab, 500 mg/m2 every 2 weeks, since May 17, 2018. CT after 1 month of combination treatment demonstrated obvious shrinkage in pulmonary hilar mass and pleural thickening, contributing to an evaluation of partial response (Fig. 2). Treatment-related AEs included grade 3 rash and diarrhea. Thus, the patient's dose of afatinib was decreased to 30 mg daily. In addition, on August 9, 2018, his dose of cetuximab was reduced to 250 mg/m2 owing to economic problems. CT after the dose decrease still showed a slight decrease in pleural effusion and lymph node size (see Fig. 2). The patient continued receiving the combination therapy until April 30, 2019, at which time an enlarged hilar mass was found through CT, with a progression-free survival of 11.6 months. As for the lower dose of both medications, the patient achieved a durable response for more than 8.8 months.Figure 2Chest computed tomography images before (at baseline) and after treatment with afatinib plus cetuximab.View Large Image Figure ViewerDownload Hi-res image Download (PPT) To the best of our knowledge, this EGFRM766delinsMATL is a novel EGFRex20ins mutation that has never before been reported. The patient achieved a partial response with a progression-free survival of 11.6 months. Even after dose reduction resulting from intolerable AEs, the patient still achieved a durable response. In conclusion, this study identified a novel EGFRex20ins mutation responsive to afatinib and cetuximab combination treatment. Moreover, the effect and tolerability of afatinib, 30 mg/d, plus cetuximab, 250 mg/m2 every 2 weeks, that was shown in this case might provide a potential dose choice in further clinical studies. This work was financially supported by the National Key R&D Program of China (grants 2016YFC0905500 and 2016YFC0905503), Chinese National Natural Science Foundation (grants 81772476, 81602005, 81872499, and 81702283), Science and Technology Program of Guangdong (grant 2017B020227001), and Science and Technology Program of Guangzhou (grant 201607020031).